Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Complex formulation of 3-hydroxy-3-methyl glutaryl coa reductase inhibitor and antihypertensive agent, and process for preparing same

A reductase inhibitor and anti-hypertensive technology, applied in pill delivery, drug combination, pharmaceutical formula, etc., can solve the problems that the therapeutic effect cannot be maintained for a long time, liver toxicity, etc.

Inactive Publication Date: 2007-12-19
HANMI PHARMA
View PDF8 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, Caduet  (Pfizer), a commercially available atrovastatin-amlodipine combination dosage form, has the problem of rapid release of both drugs causing hepatotoxicity, while its therapeutic effect cannot be maintained for a long time

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Complex formulation of 3-hydroxy-3-methyl glutaryl coa reductase inhibitor and antihypertensive agent, and process for preparing same
  • Complex formulation of 3-hydroxy-3-methyl glutaryl coa reductase inhibitor and antihypertensive agent, and process for preparing same
  • Complex formulation of 3-hydroxy-3-methyl glutaryl coa reductase inhibitor and antihypertensive agent, and process for preparing same

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1 to 3 and comparative example 1

[0062] Examples 1 to 3 and Comparative Example 1: Preparation of Solid Dispersion

[0063]Simvastatin (Hanmi Fine Chemical Co., Ltd., Korea), MYRJ (ICI, USA), HPMC 2910 (viscosity: 3 to 15cps, Shin-Etsu, Japan), BHT (UENO Fine Chemical, USA) and light Quality anhydrous silicic acid (as a dispersant) was dissolved in a mixture of ethanol and dichloromethane according to the amounts described in Table 1, and each resulting mixture was spray-dried to obtain particles with an average particle size of 100 μm or less. solid dispersion. The solid dispersions of Examples 1 to 3 and Comparative Example 1 thus obtained are shown in Table 1.

[0064]

[0065] components

Embodiment 4 to 8

[0066] Examples 4 to 8: Preparation of sustained-release dosage forms for oral administration

[0067] According to the amounts described in Tables 2 to 4, respectively utilizing simvastatin, lovastatin or fluvastatin as active ingredients, together with MYRJ, HPMC 2910, BHT, and light anhydrous silicic acid, the procedure of Example 1 was repeated to obtain A solid dispersion is obtained. Then, each solid dispersion was mixed with xanthan gum (Kelco, USA), locust bean gum (Cesalpinia, Italy), propylene glycol alginate (ISP, USA), HPMC 2208 (viscosity: 4,000 to 100,000 cps, Shin -Etsu, Japan) and erythorbic acid were mixed for about 30 minutes; and sucrose fatty acid ester and light anhydrous silicic acid powder (finer than 40 mesh) were added and mixed for 5 minutes. Each of the resulting mixtures was molded into a block using a molding assembly, and the block was pulverized into particles having a mesh size ranging from 20 to 80. The granules are then formulated into tab...

Embodiment 9 to 11

[0074] Examples 9 to 11: Preparation of combination dosage forms for oral administration

[0075] Each sustained-release dosage form obtained in Examples 5, 7 and 8 was coated with Opadry  AMB (Colorcon) film. Amlodipine camphorsulfonate (Hanmi Fine Chemical Co., Ltd., Korea), HPMC 2910 (viscosity: 3 to 15 cps) and acetylated monoglyceride (Myvacet) were dissolved respectively according to the amounts described in Table 5 In a mixture of ethanol and dichloromethane, it was applied to the film-coated formulations described above.

[0076]

[0077] components

(mg / tablet)

Example 9

Example 10

Example 11

Sustained-release dosage form core

Example 5

Example 7

Example 8

Active into

Minute

Ammonium D-camphorsulfonate

Clodipine

7.9

7.9

7.9

coating agent

HPMC 2910

10

10

10

plasticizer

Myvacet

1.6

1.6

1.6

stabilizer ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
diameteraaaaaaaaaa
Login to View More

Abstract

A complex formulation for oral administration comprising a sustained release formulation of an HMG-CoA reductase inhibitor and a film layer for rapid release of an anti-hypertensive agent, the film layer being coated on the sustained release formulation, can achieve improved therapeutic effects of the anti-hypertensive agent by promptly releasing it, while maintaining a constant drug level of the HMG-CoA reductase inhibitor in blood through a slow release. Accordingly, the complex formulation is useful for preventing and treating diseases such as hyperlipidemia, atherosclerosis, hypertension and cardiovascular disease.

Description

field of invention [0001] The present invention relates to a combined dosage form for oral administration comprising a sustained release dosage form of a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor and a rapid release film layer of an antihypertensive agent; and its preparation method. Background of the invention [0002] Hypercholesterolemia, a representative example of hyperlipidemia, is caused by elevated serum LDL (low-density lipoprotein)-cholesterol and total cholesterol levels, and in serum by reducing lipids especially LDL-cholesterol Treating hypercholesterolemia at low levels can reduce the risk of cardiovascular disorders leading to delayed progression of arteriosclerosis (American diabetes association, Diabetic care, 23 (suppl.), S57-565, 2000). Therefore, there have been many studies on lipid-lowering therapy to delay the progression of arteriosclerosis or alleviate arteriosclerosis in order to reduce the risk of cardiovascular disorders...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/366
CPCA61K31/366A61K9/205A61K9/209A61K31/4422A61K45/06A61P3/06A61P9/12A61K2300/00A61K9/00A61K31/44
Inventor 禹钟守池文爀金用镒
Owner HANMI PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com